Home / Pharmaceuticals / Oncology Biosimilars Market By Drug Class (Monoclonal Antibodies, Granulocyte Colony-Stimulating Factor), By Disease Condition (Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Blood Cancer, Neutropenia, Others) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026

Oncology Biosimilars Market By Drug Class (Monoclonal Antibodies, Granulocyte Colony-Stimulating Factor), By Disease Condition (Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Blood Cancer, Neutropenia, Others) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026

Published: Jul 2018 | Report Code: 59205-07-18

Industry Outlook

The oncology biosimilars market stood at US$ 1,651.5 Mn in 2017 and projected to exhibit a double-digit compound annual growth rate (CAGR) of 28.3% during the forecast period from 2018 to 2026. According to U.S. Food and Drug Administration, biosimilars are biological medicines that contain a highly similar version of the active substance of an already approved biologic, commonly referred to as the reference product. Sandoz’s Zarxio (filgrastim-sndz) and Cephalon’s Granix (tbo-filgrastim) were the first biosimilars to be approved in the U.S. and Europe for cancer supportive care. However, 2017 turned out to be the pivotal year in oncology biosimilars as Amgen’s Mvasi (bevacizumab-awwb) and Mylan’s Ogivri (trastuzumab-dkst), biosimilars to Genentech’s Avastin and Herceptin respectively received approval in United States. Mvasi is approved for the treatment of lung, colorectal, kidney, brain and cervical cancers; whereas Orivri is approved for treating breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+).  Moreover, Sandoz and Celltrion Healthcare also received European Commission approval for Rixathon (rituximab) and Truxima (rituximab) for treatment of certain types of blood cancers. Strong oncology biosimilar pipeline is further anticipated to drive the market growth during the forecast period. Europe dominated the global oncology biosimilars market on account of presence of more approved biosimilars in the region compared to other regions. Moreover, organized regulatory bodies to monitor oncology biosimilar approvals are further driving the market in Europe. North America expected to grow at the fastest growth rate during the forecast period due to recent approvals of major breakthrough biosimilars, patent expirations and robust pipeline candidates anticipated to enter the market during the forecast period.

Market Synopsis

Oncology Biosimilars Market

Robust Pipeline of Monoclonal Antibodies to Drive the Market Growth

In 2017, Granulocyte Colony-Stimulating Factor (G-CSF) lead the market by drug class segment; however, monoclonal antibodies class will continue to rise post approval showcasing excellent growth during the forecast period. Currently, approximately 30 percent of all the biosimilars in the pipeline that await FDA approval are monoclonal antibodies. This highlights the potential of monoclonal antibodies in treatment of chronic diseases in terms of efficacy and improved patient access and affordability especially for a disease like cancer. Currently there are only three biosimilar monoclonal antibodies approved for treating cancer. However, experts predict that the number will surge in the near future driven by continuous efforts for reducing healthcare costs, strong pipeline and biologics that are on the verge of losing their patent exclusivity globally by 2020.

Oncology Biosimilars Market

Constant Rise of Cancer Prevalence to Showcase Double Digit CAGR for Oncology Biosimilars during the Forecast Period

Cancer accounts for one in six deaths globally, claiming more lives than AIDS, tuberculosis and malaria combined. According to International Agency of Research on Cancer (IARC), there were 14.8 million new cases of cancer and 8.8 million cancer deaths in 2015, worldwide. This number projected to grow to 21.7 million new cases and 13 million deaths due to cancer by 2030 owing to growing geriatric population. Breast cancer is anticipated to witness tremendous growth during the forecast period, as it is the most common type of cancer in women, globally. Approximately, 1 in 8 women (i.e 12.4%) are at a risk of developing breast cancer in United States. In 2018, over 266,120 new cases of invasive breast cancer are expected to be diagnosed in the United States. China has also observed surge in the breast cancer incidence rate in last decade. For instance, an analysis from China’s national cancer registry reveals that breast cancer rate has increased around 3.5% per year from 2000 to 2014. Thus, high prevalence coupled with biosimilar approvals for breast cancer treatment would drive the oncology biosimilars market.

Oncology Biosimilars Market

Increasing Approvals in North America to set the stage for swift growth during the forecast period

In 2017, Europe occupied largest share of the global market share for oncology biosimilars. The key factors responsible for the Europe market growth are availability of more oncology biosimilars in the region, organized approval and regulatory scenarios and high cancer prevalence. However, North America projected to surge at highest growth rate owing to approvals of biosimilars for treatment of wide range of cancers. Moreover, more than 12 products await FDA approval for market entry in North America, which would set a stage of rapidgrowth of the region. Rising prevalence of cancer, enhanced funding by the pharmaceutical companies in the R&D segment, rising awareness towards biosimilars and curbing healthcare cost would result in market growth.

Oncology Biosimilars Market

Historical & Forecast Period

2016 – Historical Year
2017 – Base Year
2018-2026 – Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments calculated for the forecast period from 2018 to 2026.

Oncology Biosimilars Market

Report Scope by Segments

Oncology biosimilars market report furnishes quantitative analysis along with its latest market trends. The market is segmented based on drug classes, by disease conditions and geography.

By Drug Class (2016–2026; US$ Mn)

  • Monoclonal Antibodies
  • Granulocyte Colony-Stimulating Factor (G-CSF)
  • Pipeline Analysis
    • Phase III Molecules Analysis
      • Rituximab Biosimilar
      • Trastuzumab Biosimilar
      • Filgrastim Biosimilar
      • Bevacizumab Biosimilar
  • Phase I and Phase II Molecules Analysis

By Disease Condition (2016–2026; US$ Mn)

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Blood Cancer
  • Neutropenia
  • Others (Brain Cancer, Stomach Cancer, etc)

Geography Segment (2016–2026; US$ Mn)

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • Japan
    • Rest of APAC
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • GCC
    • Rest of Middle East and Africa

Market is studied in order to understand the current and future market trends in the oncology biosimilars market. The market is estimated by providing the compounded annual growth rate (CAGR) and data forecast from 2018 to 2026. Product portfolio provided in the report gives information of the approved biosimilars prescribed for the treatment of cancer. Strategic acquisition, merger and collaboration among the key players for developing innovative product pipeline mentioned in the business strategy section. The key players currently engaged in the oncology biosimilars market are Samsung Bioepis Co. Ltd., Celltrion Inc., Biocon, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Sandoz, Inc., Teva Pharmaceutical Industries Ltd., Apotex Inc., and BIOCAD.

Key questions answered in this report

  • How the global oncology biosimilars market will perform during the forecast period from 2018 to 2026?
  • What are the latest trends in the oncology biosimilars market and valuable opportunities for key players?
  • Who are the leading players in the global oncology biosimilars market?
  • Which is the leading/and fastest region in the global oncology biosimilars market?
  • Currently, what are the approval guidelines for the oncology biosimilars?
  • What impact would the pipeline drugs have on the global oncology biosimilars market?
  • What are drivers and restrains governing the global oncology biosimilars market?

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Oncology Biosimilars Market Portraiture
2.2. Global Oncology Biosimilars Market, by Drug Class, 2017 (US$ Mn)
2.3. Global Oncology Biosimilars Market, by Disease Condition, 2017 (US$ Mn)
2.4. Global Oncology Biosimilars Market Share, by Geography, 2017 (US$ Mn)

Chapter 3. Oncology Biosimilars: Market Dynamics and Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Oncology Biosimilars Market, by Key Players, 2017

Chapter 4. Global Oncology Biosimilars Market, by Drug Class, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Monoclonal Antibodies
4.3. Granulocyte Colony-Stimulating Factor (G-CSF)
4.4. Pipeline Analysis
4.4.1. Phase III Drug Analysis
4.4.1.1. Rituximab Biosimilar
4.4.1.2. Trastuzumab Biosimilar
4.4.1.3. Filgrastim Biosimilar
4.4.1.4. Bevacizumab Biosimilar
4.4.2. Tabular Representation of Phase I and Phase II Drugs

Chapter 5. Global Oncology Biosimilars Market, by Disease Condition, 2016-2026 (US$ Mn)
5.1. Overview
5.2. Breast Cancer
5.3. Lung Cancer
5.4. Colorectal Cancer
5.5. Cervical Cancer
5.6. Blood Cancer
5.7. Neutropenia
5.8. Others (Brain Cancer, Stomach Cancer, etc.)

Chapter 6. Global Oncology Biosimilars Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.1.1. North America Oncology Biosimilars Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.1.2. North America Oncology Biosimilars Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.1.3. North America Oncology Biosimilars Market, by Country, 2016 – 2026 (US$ Mn)
6.1.3.1. U.S.
6.1.3.2. Canada
6.2. Europe Oncology Biosimilars Market Analysis, 2016 – 2026
6.2.1. Europe Oncology Biosimilars Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.2.2. Europe Oncology Biosimilars Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.2.3. Europe Oncology Biosimilars Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.2.3.1. U.K.
6.2.3.2. Germany
6.2.3.3. Rest of Europe
6.3. Asia Pacific Oncology Biosimilars Market Analysis, 2016 – 2026
6.3.1. Asia Pacific Oncology Biosimilars Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.3.2. Asia Pacific Oncology Biosimilars Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.3.3. Asia Pacific Oncology Biosimilars Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. China
6.3.3.2. Japan
6.3.3.3. Rest of Asia Pacific
6.4. Latin America Oncology Biosimilars Market Analysis, 2016 – 2026
6.4.1. Latin America Oncology Biosimilars Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.4.2. Latin America Oncology Biosimilars Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.4.3. Latin America Oncology Biosimilars Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. Brazil
6.4.3.2. Mexico
6.4.3.3. Rest of Latin America
6.5. Middle East & Africa Oncology Biosimilars Market, 2016 – 2026
6.5.1. Middle East & Africa Oncology Biosimilars Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.5.2. Middle East &Africa Oncology Biosimilars Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.5.3. Middle East & Africa Oncology Biosimilars Market Analysis, by Region, 2016 – 2026 (US$ Mn)
6.5.3.1. GCC
6.5.3.2. Rest of Middle East & Africa

Chapter 7. Company Profiles
7.1. Amgen, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to Data Availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Mylan N.V.
7.3. Samsung Bioepis Co. Ltd.
7.4. Teva Pharmaceutical Industries Ltd.
7.5. Pfizer, Inc.
7.6. Celltrion Healthcare
7.7. Novartis International AG
7.8. Biocon Limited
7.9. Biogen Idec
7.10. Sandoz
7.11. Dr. Reddy’s Laboratory
7.12. Merck & Co.
7.13. Shanghai Henlius Biotech, Inc.
7.14. Biocad

Note :

Modification in the list of company profiles or scope of the study can be incorporated on request.

FIG 1. Oncology Biosimilars Market: Research Methodology
FIG 2. Oncology Biosimilars: Market Segmentation
FIG 3. Global Oncology Biosimilars Market, by Drug Class, 2017 (US$ Mn)
FIG 4. Global Oncology Biosimilars Market, by Disease Condition, 2017 (US$ Mn)
FIG 5. Global Oncology Biosimilars Market, by Geography, 2017 (US$ Mn)
FIG 6. Attractive Investment Proposition, by Geography, 2017
FIG 7. Competitive Analysis: Global Oncology Biosimilars Market, by Key Players, 2017
FIG 8. Global Monoclonal Antibodies Market in Oncology Biosimilars, 2016-2026(US$ Mn)
FIG 9. Global Granulocyte Colony-Stimulating Factor (G-CSF) Market in Oncology Biosimilars, 2016-2026 (US$ Mn)
FIG 10. Global Rituximab Biosimilar Market in Oncology Biosimilars, 2016-2026(US$ Mn)
FIG 11. Global Trastuzumab Biosimilar Market in Oncology Biosimilars, 2016-2026 (US$ Mn)
FIG 12. Global Filgrastim Biosimilar Market in Oncology Biosimilars, 2016-2026(US$ Mn)
FIG 13. Global Bevacizumab Biosimilar Market in Oncology Biosimilars, 2016-2026 (US$ Mn)
FIG 14. Global Breast Cancer Treatment in Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 15. Global Lung Cancer Treatment in Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 16. Global Colorectal Cancer Treatment in Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 17. Global Cervical Cancer Treatment in Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 18. Global Blood Cancer Treatment in Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 19. Global Neutropenia Treatment in Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 20. Global Others Cancer Treatment in Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 21. U.S. Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 22. Canada Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 23. U.K. Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 24. Germany Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 25. Rest of Europe Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 26. China Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 27. Japan Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 28. Rest of Asia Pacific Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 29. Brazil Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 30. Mexico Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 31. Rest of Latin America Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 32. GCC Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 33. Rest of Middle East & Africa Oncology Biosimilars Market, 2016-2026 (US$ Mn)

TABLE 1 Global Oncology Biosimilars Market Portraiture
TABLE 2 Global Oncology Biosimilars Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 3 Pipeline Analysis: Phase I and Phase II Drugs
TABLE 4 Global Oncology Biosimilars Market, by Disease Condition, 2016 – 2026 (US$ Mn)
TABLE 5 Global Oncology Biosimilars Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 6 North America Oncology Biosimilars Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 7 North America Oncology Biosimilars Market, by Disease Condition, 2016 – 2026 (US$ Mn
TABLE 8 North America Oncology Biosimilars Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 9 Europe Oncology Biosimilars Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 10 Europe Oncology Biosimilars Market, by Disease Condition, 2016 – 2026 (US$ Mn)
TABLE 11 Europe Oncology Biosimilars Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 Asia Pacific Oncology Biosimilars Market, by Drug Condition, 2016 – 2026 (US$ Mn)
TABLE 13 Asia Pacific Oncology Biosimilars Market, by Disease Type, 2016 – 2026 (US$ Mn)
TABLE 14 Asia Pacific Oncology Biosimilars Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 15 Latin America Oncology Biosimilars Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 16 Latin America Oncology Biosimilars Market, by Disease Condition, 2016 – 2026 (US$ Mn
TABLE 17 Latin America Oncology Biosimilars Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 18 Middle East & Africa Oncology Biosimilars Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 19 Middle East & Africa Oncology Biosimilars Market, by Disease Condition, 2016 – 2026 (US$ Mn)
TABLE 20 Middle East & Africa Oncology Biosimilars Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 21 Amgen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Mylan N.V.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Samsung Bioepis Co. Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Celltrion Healthcare: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Novartis International AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 Biocon Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Biogen Idec: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 30 Dr. Reddy’s Laboratory: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 31 Merck & Co.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 32 Shanghai Henlius Biotech, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 33 Biocad: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients